Harvesting, expanding, and banking of human adipose-derived mesenchymal stem cells: Creating personalized cell banks

Michael L Moeller
American CryoStem Corporation, USA

Autologous stem cell therapies permit a therapeutic approach devoid of the possibility of transplant rejection, the need for immunosuppressive therapies or any potential problems which might arise from transmitted pathologies. It is also attractive as it offers a “self-healing-self” paradigm that is appealing to many. It has been long been known that mesenchymal stem cells (MSCs) are largely resident in the perivascular niche surrounding blood vessels throughout the human body. Any tissue that is highly vascularized can conceivably serve as a robust and reliable source of MSCs, including adipose tissue obtained from liposuction procedures. In this presentation, we will look at American CryoStem, a small but growing biotech focused on the collection, expansion, and banking of client-specific adipose tissue and mesenchymal stem cells.

Biography
Michael L Moeller, PhD is the current Chief Scientist of American CryoStem Corporation, where he has applied his nearly 20 years of work in Human Tissue-derived Stem Cell Biology to develop and commercialize new reagents and technical platforms for the collection, expansion, differentiation, banking and application of human adipose-derived mesenchymal stem cells.

mike.moeller@wellsfargoadvisors.com